. Author manuscript; available in PMC: 2009 Dec 1.

Published in final edited form as: Clin Cancer Res. 2008 Dec 1;14(23):7900–7908. doi: 10.1158/1078-0432.CCR-08-0415

Table 4.

Summary of topotecan and lapatinib pharmacokinetics

Drug	Topotecan alone (day 1)^*	Lapatinib + topotecan (day 8)^*	Day 8:day 1 ratio^†
Topotecan (n = 9)
C_max (ng/mL)	162 (146–178)	128 (102–154)	0.79 (0.66–0.92)
AUC0–24 h (h·ng/mL)	432 (329–535)	510 (323–697)	1.18 (1.07–1.29)
CL_p (L/h/m²)	7.28 (5.35–8.91)	6.14 (4.27–8.01)	0.84 (0.76–0.92)
CL_NRF (L/h/m²)	5.25 (3.99–6.51)	4.11 (2.72–5.50)	0.78 (0.68–0.88)
t_1/2 (h)	4.30 (4.09–4.51)	4.35 (3.96–4.74)	1.01 (0.96–1.06)
V_ss (L/m²)	30.5 (26.5–34.5)	30.1(23.9–36.3)	0.99 (0.90–1.08)
	Lapatinib alone (day 7)^*	Lapatinib + topotecan (day 8)^*	Day 8:day 7 ratio^†

Lapatinib (n = 9)
C_max (µg/mL)	1.89 (1.33–2.68)	2.33 (1.78–3.05)	1.24 (1.00–1.52)
T_max (h)	3.00 (2.59–8.00)^‡	4.00 (1.50–12.0)^‡	0.25 (−4.00 to 9.00)^§
AUC_{0–24 h} (h·µg/mL)	23.3 (14.5–37.3)	31.7 (22.6–44.5)	1.36 (1.04–1.78)

Geometric mean and 95% confidence intervals unless otherwise indicated.

^†

Geometric least squares mean ratio and 90% confidence intervals unless otherwise indicated.

^‡

Median and range.

^§

Median and range of pairwise differences.